Search Result

Results for "

S1P1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Endogenous Metabolite (2) ERK (1) Isotope-Labeled Compounds (3) LPL Receptor (57) PAK (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (5) Endocrinology (3) Inflammation/Immunology (39) Metabolic Disease (2) Neurological Disease (16)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12835

S1P1 agonist III	LPL Receptor	Inflammation/Immunology
S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.

HY-115831

SAR247799 S1P1 agonist 3	LPL Receptor	Cardiovascular Disease
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased *sphingosine-1 phosphate receptor-1 (S1P1* )** agonist, with EC₅₀s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome .

HY-117213

Ex26 S1P1-IN-Ex26	LPL Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1 (S1P₁) antagonist (IC₅₀=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P₁ over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach .

HY-18166

NIBR0213	LPL Receptor	Inflammation/Immunology
NIBR-0213 is a potent, orally active and selective *S1P1* antagonist with efficacy in experimental autoimmune encephalomyelitis. NIBR-0213 displays potent and comparable potency on human and rat S1P1 (IC₅₀ of 2.0 nM and 2.3 nM, respectively) in GTPγ ³⁵S assays .

HY-156565

S1P1 agonist 6	LPL Receptor	Inflammation/Immunology
S1P1 agonist 6 (Compound I) is a *S1P1* agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 can be used as an immunosuppressive agent in the study of various autoimmune diseases research .

HY-144126

S1P1 agonist 5	LPL Receptor	Inflammation/Immunology
S1P1 agonist 5 is a selective and orally active *S1P1* agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) .

HY-156565A

S1P1 agonist 6 hemicalcium	LPL Receptor	Inflammation/Immunology
S1P1 agonist 6 hemicalcium (Compound I) is a *S1P1* agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 hemicalcium can be used as an immunosuppressive agent in the study of various autoimmune diseases research .

HY-145362

S1P1 agonist 4	LPL Receptor	Others
S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

HY-120468

GSK2263167	LPL Receptor	Inflammation/Immunology
GSK2263167 is a S1P1 receptor agonist

HY-118919

CYM5181	LPL Receptor	Others
CYM5181 is a novel *S1P1* agonist with a pEC₅₀ value of -8.47 .

HY-10569

Ponesimod 2 Publications Verification ACT-128800	LPL Receptor	Inflammation/Immunology
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of *S1P₁, with an IC₅₀* of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-120633A

BMS-986104 hydrochloride	LPL Receptor	Inflammation/Immunology
BMS-986104 hydrochloride is a selective S1P1 receptor partial agonist, and can be used for research of autoimmune diseases .

HY-16734A

Amiselimod hydrochloride MT-1303 hydrochloride	LPL Receptor	Cancer
Amiselimod hydrochloride is an orally active novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod-P shows potent and high selectivity for *S1P1* and S1P5 but with minimal agonist activity for S1P4 and no distinct agonist activity for S1P2 or S1P3. Amiselimod hydrochloride is promising for research of autoimmune diseases .

HY-10968A

CYM5442 hydrochloride	LPL Receptor	Neurological Disease
CYM5442 hydrochloride is a potent, highly-selective and orally active *sphingosine 1-phosphate (S1P1) receptor* agonist with an EC₅₀ of 1.35 nM. CYM5442 hydrochloride is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 hydrochloride activates *S1P1*-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 hydrochloride can easily penetrate the central nervous system (CNS) .

HY-10968

CYM5442 1 Publications Verification	LPL Receptor	Neurological Disease
CYM5442 is a potent, highly-selective and orally active *sphingosine 1-phosphate (S1P1) receptor* agonist with an EC₅₀ of 1.35 nM. CYM5442 is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 activates *S1P1*-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 can easily penetrate the central nervous system (CNS) .

HY-116088

W123	LPL Receptor	Inflammation/Immunology
W123, a FTY720 analog, is a competitive *sphingosine 1-phosphate type 1 (S1P1) receptor* antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization .

HY-108493

CS-2100	LPL Receptor	Inflammation/Immunology
CS-2100 (Compound 10b) is a potent, selective, orally active and S1P₃-sparing *S1P₁* agonist with an EC₅₀ of 4.0 nM for human S1P₁. CS-2100 shows in vivo immunosuppressive efficacy in rats with an ID₅₀ (infective dose) of 0.407 mg/kg for HvGR .

HY-132847

Vibozilimod SCD-044	LPL Receptor	Others
Vibozilimod (SCD-044, example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1) .

HY-W701470

W140 hydrobromide	LPL Receptor	Inflammation/Immunology
W140 hydrobromide is a *S1P1* antagonist with the K_i of 2.84 μM, and can enhanceof capillary leakage and restoration of lymphocyte egress .

HY-10569S

Ponesimod-d4 ACT-128800-d₄	Isotope-Labeled Compounds LPL Receptor	Others
Ponesimod-d₄ (ACT-128800-d₄)is the deuterium labeledPonesimod(HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of *S1P₁, with an IC₅₀* of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-W008947

SEW2871 5 Publications Verification	LPL Receptor ERK Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective *S1P1* (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .

HY-101939

RP-001	LPL Receptor	Neurological Disease
RP-001 is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC₅₀ of 9 pM. RP-00 induces internalization and polyubiquitination of S1P1. RP-001 has little activity on S1P2-S1P4 and only moderate affinity for S1P5 .

HY-101939A

RP-001 hydrochloride	LPL Receptor	Neurological Disease
RP-001 hydrochloride is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC₅₀ of 9 pM. RP-00 hydrochloride induces internalization and polyubiquitination of S1P1. RP-001 hydrochloride has little activity on S1P2-S1P4 and only moderate affinity for S1P5 .

HY-120611A

BMS-960	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
BMS-960 is a potent and selective *S1P₁* receptor agonist containing isoxazole, which can be used in the research of immune diseases and vascular diseases .

HY-157787

Ginkgolic acid 2-phosphate	LPL Receptor	Neurological Disease
Ginkgolic acid 2-phosphate is a potent sphingosine 1-phosphate agonist. Ginkgolic acid 2-phosphate induces ERK phosphorylation. Ginkgolic acid 2-phosphate interactes with S1P1 .

HY-12789

Etrasimod 1 Publications Verification APD334	LPL Receptor	Inflammation/Immunology
Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P₁) receptor with an IC₅₀ value of 1.88 nM in CHO cells.

HY-120611

BMS-960 free base	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
BMS-960 free base is a potent and selective *S1P₁* receptor agonist containing isoxazole, which can be used in the research of immune diseases and vascular diseases .

HY-10569S1

Ponesimod-d7 ACT-128800-d₇	Isotope-Labeled Compounds	Others
Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of *S1P₁, with an IC₅₀* of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-17606

Cenerimod ACT-334441	LPL Receptor	Inflammation/Immunology
Cenerimod (ACT-334441) is a potent, selective and orally active S1P1 receptor modulator, with an EC₅₀ of 1 nM. Cenerimod shows more than 36 fold selctivity for hS1P1 over hS1P2, hS1P3, hS1P4, and hS1P5 receptor subtypes (EC₅₀s=>10000, 228, 2134, and 36 nM, respectively). Cenerimod can attenuate murine experimental autoimmune encephalomyelitis (EAE) and murine sclerodermatous .

HY-12355

Siponimod Maximum Cited Publications 8 Publications Verification BAF-312	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for *S1P₁* and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^- .

HY-14977

CS-0777-P	LPL Receptor	Inflammation/Immunology
CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS) .

HY-12355A

Siponimod hemifumarate BAF-312 hemifumarate	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for *S1P1* and S1P5 receptors over S1P2, S1P3, and S1P4 (EC₅₀s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research .

HY-111021

ASP-4058 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-111021A

ASP-4058 hydrochloride 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-12616

ACT-209905	LPL Receptor	Cancer
ACT-209905 is a S1P1 receptor agonist. ACT-209905 can inhibit glioblastoma (GBM) cell growth and migration. ACT-209905 also has immunomodulating activity, and can be used in research of autoimmune diseases .

HY-12355R

Siponimod (Standard)	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (Standard) is the analytical standard of Siponimod. This product is intended for research and analytical applications. Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for *S1P₁* and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^- .

HY-114061

(R)-FTY 720P	Others	Others
(R)-FTY 720P is the R-isomer of FTY 720P. (R)-FTY 720P has less potent binding affinities to S1P_1,3,4,5 than (S)-Isomer (HY-15382) .

HY-16734

Amiselimod MT-1303	LPL Receptor	Inflammation/Immunology
Amiselimod (MT-1303) is a modulator for sphingosine 1-phosphate receptor (S1P receptor). Amiselimod converses to its active metabolite (S)-amiselimod phosphate by sphingosine kinases (SPHKs), targets S1P1 receptor, ameliorates the autoimmune disease without causing bradycardia .

HY-16622A

GSK 1842799 TFA	LPL Receptor	Others
GSK1842799, an alkyl-substituted biaryl amino alcohol, is a selective S1P1 modulator developed for multiple sclerosis (MS). Upon phosphorylation, GSK1842799-P exhibited subnanomolar S1P1 agonist activity with over 1000-fold selectivity over S1P3. The compound showed good oral bioavailability, rapid in vivo conversion to GSK1842799-P, and significant lymphocyte count reduction at 0.1 mg/kg. It matched FTY720 efficacy at 3 mg/kg in the mouse EAE model and achieved comparable plasma levels to FTY-720 phosphate in cynomolgus monkeys. With favorable ADME, PK/PD properties, and toxicology, GSK1842799 advanced to further clinical development .

HY-120633

BMS-986104	LPL Receptor
BMS-986104 is a potent and selective S1P1 receptor modulator. BMS-986104 is effective in a mouse EAE model, which is comparable to FTY720. Mechanistically, BMS-986104 exhibites excellent remyelinating effects on lysophosphatidylcholine (LPC)-induced demyelination in a three-dimensional brain cell culture assay.

HY-19511

GSK2018682	LPL Receptor	Inflammation/Immunology
GSK2018682 is an agonist for *S1P1* and S1P5 receptor with pEC₅₀s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.

HY-18164

TASP0277308	LPL Receptor	Inflammation/Immunology
TASP0277308 is a highly selective S1P₁ antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice .

HY-135432

Etrasimod arginine APD334 arginine	LPL Receptor	Inflammation/Immunology
Etrasimod arginine is an orally available S1P receptor modulator that is a potent full agonist of the *S1P1 receptor and has partial agonist activity at S1P*4. Etrasimod arginine reduces inflammation in a CD4 ⁺CD45RB ^high T cell-transferred mouse colitis model .

HY-19511A

GSK2018682 hydrochloride	LPL Receptor	Inflammation/Immunology
GSK2018682 hydrochloride is an agonist for *S1P1* and S1P5 receptor with pEC₅₀s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 hydrochloride is used in the research of multiple sclerosis.

HY-108492

TC-SP 14	LPL Receptor	Inflammation/Immunology
TC-SP 14 (compound 14) is an orally active and potent *S1P1* agonist (EC₅₀ = 0.042 μM) with minimal activity at S1P3 (EC₅₀ = 3.47 μM). TC-SP 14 significantly reduces blood lymphocyte counts and attenuates a delayed type hypersensitivity (DTH) response to antigen challenge .

HY-101265

Icanbelimod S1p receptor agonist 1	LPL Receptor	Inflammation/Immunology
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.

HY-108490

VPC 23019	LPL Receptor	Inflammation/Immunology
VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the *S1P1* and S1P3 receptors (pK_i= 7.86 and 5.93, respectively) and an agonist at the S1P4 and S1P5 receptors (pEC₅₀= 6.58 and 7.07, respectively) .

HY-119221A

AUY 954 hydrochloride	Others	Neurological Disease
AUY 954 hydrochloride is a potent and selective sphingosine-1-phosphate (S1P(1)) receptor agonist, exhibiting significant immunomodulatory activity. AUY 954 hydrochloride induces a profound and reversible reduction of circulating lymphocytes upon oral administration. AUY 954 hydrochloride has demonstrated efficacy in prolonging cardiac allograft survival when used in combination with RAD001 in a stringent transplantation model. AUY 954 hydrochloride effectively prevents experimental autoimmune neuritis in rats, showcasing its therapeutic potential in autoimmune conditions.

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the *S1P1* and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

HY-108494

CYM50260	LPL Receptor	Cardiovascular Disease
CYM50260 is a potent and exquisitely selective sphingosine-1-phosphate 4 receptor (S1P₄-R) agonist with an EC₅₀ of 45 nM. CYM50260 displays no activity against S1P₁-R, S1P₂-R, S1P₃-R and S1P₅-R .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108496

Sphingosine-1-phosphate 5+ Cited Publications S1P	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite LPL Receptor
Sphingosine-1-phosphate (S1P) is an agonist of S1P_1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca ²⁺ as an extracellular ligand for G protein-coupled receptors . Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids .

Cat. No.	Product Name	Chemical Structure

HY-10569S1

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-108496S

Sphingosine-1-phosphate-d7

Sphingosine-1-phosphate-d₇ is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].

HY-10569S

Ponesimod-d4
Ponesimod-d₄ (ACT-128800-d₄)is the deuterium labeledPonesimod(HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of *S1P₁, with an IC₅₀* of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-12355S

Siponimod-d11
Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for *S1P₁* and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81494

	EDG1 Antibody (YA1239) S1PR1; EDG1; S1P1; ECGF1; EDG-1; CHEDG1; D1S3362	IHC-P	Human
	EDG1 Antibody (YA1239) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1239), targeting EDG1. EDG1 Antibody (YA1239) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks